These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25903741)

  • 1. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
    Luthra P; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1227-36. PubMed ID: 25903741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
    Ford AC; Peyrin-Biroulet L
    Am J Gastroenterol; 2013 Aug; 108(8):1268-76. PubMed ID: 23649185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
    Williams CJ; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Sandborn WJ; Khan KJ; Hanauer SB; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):644-59, quiz 660. PubMed ID: 21407183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.
    Shah ED; Farida JP; Siegel CA; Chong K; Melmed GY
    Inflamm Bowel Dis; 2017 Apr; 23(4):570-577. PubMed ID: 28230558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Bernstein CN; Khan KJ; Abreu MT; Marshall JK; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):590-9; quiz 600. PubMed ID: 21407179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007571. PubMed ID: 19160337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Vedolizumab Treatment and Arthritis/Arthralgia in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Alves Halpern G; Gomes C; Thaytala Quintino Falcon B; Prigol Dalfovo M; De Carvalho Maia J; Brandão Oliveira D
    J Gastrointestin Liver Dis; 2024 Sep; 33(3):379-385. PubMed ID: 39348571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis.
    Lin L; Liu X; Wang D; Zheng C
    Medicine (Baltimore); 2015 Mar; 94(10):e556. PubMed ID: 25761174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
    Smith MA; Mohammad RA
    Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
    Poulakos M; Machin JD; Pauly J; Grace Y
    J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.
    Wang MC; Zhang LY; Han W; Shao Y; Chen M; Ni R; Wang GN; Wei FX; Zhang YW; Xu XD; Zhang YC
    Medicine (Baltimore); 2014 Dec; 93(28):e326. PubMed ID: 25526490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
    Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
    Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Garnock-Jones KP
    BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
    Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.